Merck's Call To Action: Why Industry Should Embrace Health Reform
This article was originally published in RPM Report
Industry has much to fear about some elements of health reform, like drug importation and price negotiation under Medicare Part D. But the risks of inaction are even greater. Pharmaceutical companies need to ensure that they have a place at the table-and come with a detailed plan on how health reform should work.
You may also be interested in...
In a widely anticipated move, Merck has named current president Ken Frazier as CEO